CAJ | 학술논문

目的研究索拉非尼对肝癌术后早期肝功能及凝血功能的影响.方法经病理确诊为肝癌,术后接受索拉非尼治疗者,共30例,分析不同剂量下、服药前及服药后1个月、3个月时肝功能及凝血功能的变化.结果不同剂量对血清AST、ALT、TBIL、IBIL、ALB浓度及PT的影响均无统计学意义(P＞0.05)；服药前及服药后1个月时血清AST、ALT、TBIL、IBIL及ALB浓度变化无统计学意义(P＞0.05),而血清PT变化有统计学意义(P＜0.05).服药前及服药后3个月时血清TBIL、IBIL及ALB浓度变化无统计学意义(P＞0.05),而血清AST、ALT浓度及PT变化有统计学意义(P＜0.05).结论索拉非尼可引起肝癌术后患者早期转氨酶升高,对早期凝血功能有抑制作用,且均与剂量无关.
목적 연구색랍비니대간암술후조기간공능급응혈공능적영향.방법 경병리학진위간암,술후접수색랍비니치료자,공30례,분석불동제량하、복약전급복약후1개월、3개월시간공능급응혈공능적변화.결과 불동제량대혈청AST、ALT、TBIL、IBIL、ALB농도급PT적영향균무통계학의의(P＞0.05)；복약전급복약후1개월시혈청AST、ALT、TBIL、IBIL급ALB농도변화무통계학의의(P＞0.05),이혈청PT변화유통계학의의(P＜0.05).복약전급복약후3개월시혈청TBIL、IBIL급ALB농도변화무통계학의의(P＞0.05),이혈청AST、ALT농도급PT변화유통계학의의(P＜0.05).결론 색랍비니가인기간암술후환자조기전안매승고,대조기응혈공능유억제작용,차균여제량무관.
Objective To investigate the impacts of sorafenib on liver function and blood coagulation in patients undergoing hepatectomy.Methods 30 patients with pathologically confirmed liver cancer received sorafenib at different doses.Liver function and blood coagulation were detected in all the patients before treatment and one and three months after treatment.Results There were no statistical significances among sorafenib at different doses in levels of AST,ALT,TBIL,IBIL,ALB,and PT (P＞0.05).Concentrations of ALT,AST,TBIL,IBIL,and ALB did not change statistically one month after treatment as compared with the baseline values (P＞0.05) while PT changed significantly (P＜0.05).There were no statistical significances in concentrations of TBIL,IBIL and ALB 3 month after treatment as compared with the baselines,but levels of ALT,AST,and PT differed significantly (P＜0.05).Conclusions Sorafenib can induce an early elevation in levels of transaminases in patients undergoing hepatectomy,which plays a role in the inhibition of blood coagulation in a dose-independent fashion.